Title
Efficacy, Safety, and Tolerability of HTS-519 Insert in Patients With Toenail Fungus of the Big Toenail
An Open-Label Phase 2 Study to Investigate the Efficacy, Tolerability, and Safety of the HTS-519 Insert in the Treatment of Subjects With Distal Lateral Subungual Onychomycosis of the Great Toenail
Phase
Phase 2Lead Sponsor
Hallux, Inc.Study Type
InterventionalStatus
Completed Results PostedIndication/Condition
OnychomycosisIntervention/Treatment
htu-520 ...Study Participants
30The purpose of this study is to assess the efficacy, safety and tolerability of HTS-519 Inserts in the treatment of mild to moderate toenail fungus disease of the big toenail.
Open label, single-site
Maximum feasible dose of HTS-519 Insert per diseased nail
Inclusion Criteria: Male and females 18 - 74 years of age inclusive Fungal toenail infection of one or both of the large (great) toenails The nail infection must be due to a dermatophyte, (mixed infections [dermatophyte and non-dermatophyte] are not allowed) Willingness not to have professional pedicures or application of any nail polish product or nail cosmetics to the toenails after the screening visit Exclusion Criteria: History of any significant chronic fungal disease other than onychomycosis or immunocompromised condition Any abnormalities of the nail or previous surgery of the toenail that could prevent a normal appearing nail if clearing of infection is achieved Significant confounding conditions as assessed by the study doctor Participation in any other trial of an investigational drug or device within 30 days or participation in a research study concurrent with this study No administration of systemic antifungal medications within 6 months prior to screening visit No application of prescription topical antifungal medications for toenail fungus within 3 months or other commercially available topical medications for toenail fungus applied directly to the toenails within 1 month prior to screening visit Tinea pedis (athlete's foot) that would require systemic treatment Other protocol-defined inclusion/exclusion criteria may apply
| Event Type | Organ System | Event Term | HTS-519 Insert |
|---|
Frequency and severity of Treatment Related Adverse Events
